Given the high attrition rates, substantial costs and slow pace of new drug discovery and
development, repurposing of'old'drugs to treat both common and rare diseases is …

The Aurora kinase family is comprised of three serine/threonine kinases, Aurora‐A, Aurora‐
B, and Aurora‐C. Among these, Aurora‐A and Aurora‐B play central roles in mitosis …

Ninety-seven percent of drug-indication pairs that are tested in clinical trials in oncology
never advance to receive US Food and Drug Administration approval. While lack of efficacy …

Centrioles are ancient organelles that build centrosomes, the major microtubule-organizing
centers of animal cells. Extra centrosomes are a common feature of cancer cells. To …

Kinases are highly regulated enzymes with diverse mechanisms controlling their catalytic
output. Over time, chemical discovery efforts for kinases have produced ATP-competitive …

Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors,
including neuroblastoma. No small molecules that target N-Myc, the protein encoded by …

Amplification of MYCN is the driving oncogenic change in a subset of high-risk
neuroblastomas. The MYCN protein and the Aurora-A kinase form a complex during the S …

The mitotic kinase AURORA-A is essential for cell cycle progression and is considered a
priority cancer target. Although the catalytic activity of AURORA-A is essential for its mitotic …

Abstract N-myc (MYCN), a member of the Myc family of basic-helix–loop–helix–zipper
(bHLHZ) transcription factors, is a central regulator of many vital cellular processes. As such …

Purpose: This phase I study evaluated the safety, pharmacokinetics, pharmacodynamics,
and efficacy of the investigational oral drug MLN8237 (alisertib), a small-molecule Aurora A …